PHILADELPHIA--(BUSINESS WIRE)--iECURE (pronounced EE-ah-cure), a mutation-agnostic in vivo gene editing company striving to cure devastating diseases with high unmet need, today announced it has ...
PHILADELPHIA, March 18, 2026--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, ...
PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with ...
Add Yahoo as a preferred source to see more of our stories on Google. Gene editing company iECURE has said data from its Phase I/II ornithine transcarbamylase (OTC) deficiency trial could suggest ...
iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with significant unmet need, ...
iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at the ASGCT and SIMD Annual Meetings iECURE, Inc., a ...
PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a genome editing company focused on the development of variant-agnostic in vivo targeted gene insertion therapies for the treatment of liver disorders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results